NovoSeven RT

Indicated For

hemophilia A or B with inhibitors, congenital factor VII deficiency, Glanzmann’s thrombasthenia, acquired hemophilia

About This Medication

# Novo Nordisk Patient Assistance Program Patient Guide: How to Get NovoSeven RT (coagulation factor VIIa recombinant) at Low or No Cost NovoSeven RT (coagulation factor VIIa recombinant) is a critical medication used to treat and prevent bleeding episodes in patients with hemophilia A or B with inhibitors, factor VII deficiency, or Glanzmann's thrombasthenia. The **Novo Nordisk Patient Assistance Program (PAP)** offers this expensive specialty drug **at no cost** to eligible uninsured or underinsured patients struggling with high costs. This guide explains everything you need to know in simple terms. ## About NovoSeven RT **NovoSeven RT** is a recombinant form of coagulation **factor VIIa**, a clotting protein your body needs to stop bleeding. It's a lyophilized (freeze-dried) powder for reconstitution and injection, supplied in various strengths like 1 mg, 2 mg, 4.8 mg, and higher doses. Administered by intravenous injection, it's a **biosimilar-free** therapy with no direct alternatives listed in program details. It's essential for rare bleeding disorders where standard treatments fail, but its list price can exceed **$10,000 per dose**, making patient assistance vital[1][2][8]. ## Who Qualifies for the Program? The program targets **US citizens or legal residents** facing financial hardship. Key requirements include: - **Income at or below 400% of the Federal Poverty Level (FPL)** for your household size (most consistent across sources; some older docs mention 300% FPL)[4][6][8]. - **Uninsured or underinsured**; no active prescription coverage like HMO/PPO[10]. - **Not eligible for Medicaid** (must provide denial letter if applicable) or Medicare LIS[1][8]. - **Medicare Part D patients**: Recent policy no longer requires $1,000 out-of-pocket spend, but eligibility is limited and applications due by Nov 30[1][3][4]. **Proof of residency** (e.g., utility bill, government ID) and **US status** are required[1][6]. The program performs electronic income verification with consent[2][7]. ## Income Eligibility Breakdown Eligibility hinges on household income ≤ **400% FPL**. Use the table below for 2026 guidelines (FPL adjusts annually; check HHS.gov for exact figures). For a family of 4, 400% FPL is roughly **$120,000** annually. | Household Size | 100% FPL (approx.) | 400% FPL Threshold | |----------------|---------------------|---------------------| | 1 (Individual) | $15,060 | $60,240 | | 2 (Couple) | $20,440 | $81,760 | | 3 | $25,820 | $103,280 | | 4 | $31,200 | $124,800 | | +1 Member | +$5,380 | +$21,520 | *Notes: Include all household income sources. Specific thresholds for NovoSeven RT not detailed; call (800) 488-5908 to confirm[1][4][6].* ## Insurance Requirements - **Uninsured/underinsured only**: No active commercial, HMO, or PPO coverage[10]. - **Medicare Part D**: Eligible without $1,000 spend (updated policy), but enrollment ends calendar year-end; submit insurance ID[1][2][3][4]. - **Medicaid**: Denial letter required[1][8]. - Patients agree **not to seek government reimbursement** for provided meds[2]. ## Step-by-Step Application Process Applications use **multiple methods** (online, paper, phone/fax); involve **patient + healthcare provider (HCP)**[1][3][6]. 1. **Gather Documents**: - **Proof of income** (tax return 1040, pay stubs, SSA-1099, etc.)[1][5][6]. - **Proof of residency** (ID, utility bill)[1]. - **Proof of insurance status** (Medicare card, Medicaid denial)[1][2][6]. - HCP details (name, email, state)[6]. 2. **Start Application**: - **Online** (English only): HCP starts at NovoCare.com; you get email code to complete patient section[1][3][6]. - **Paper** (English/Spanish): Download from NovoCare, fill patient part, take to HCP for signature/prescription, fax/mail[2][4][6]. - **Phone**: Call **(800) 488-5908** or **866-310-7549** M-F 8am-8pm ET for help[1][6]. - Fax: 866-441-4190; Mail: Novo Nordisk, PO Box 370, Somerville, NJ 08876[2][4]. 3. **Consent & Submit**: Sign for electronic income/insurance verification; opt for phone/text alerts[1][2][7]. 4. **HCP Completes**: Provides prescription for 90-day supply, signs[5]. ## Timeline and Delivery - **Processing**: **2 business days** if complete; delays for missing info[1][3]. Mailed apps add 7 days[5]. - **Notification**: Mail letter to you/HCP; optional automated phone/text[1][2][3]. - **Delivery**: **10-14 business days** (up to 21) **shipped free to HCP's office** (not direct-to-patient)[1][2]. Pick up there. - **Enrollment**: 12 months; **reauthorization required** annually (new app or reorder)[2][4]. Medicare ends Dec 31[4]. ## Alternatives if Denied or Ineligible - **Reapply** with complete docs[1]. - **Other Resources**: Check NeedyMeds.org, PAN Foundation, or state programs for hemophilia/bleeding disorders[6]. - **No biosimilars** for NovoSeven RT listed[program details]. - **Copay Cards/Savings**: NovoCare.com for insured patients (not PAP)[9]. - **Bleeding Disorder Coags**: Hemophilia Federation of America or National Bleeding Disorders Foundation for grants. ## Refills and Reauthorization **Reauthorization required** yearly. HCP submits reorder form with updated income/proof; same process/timeline[2][4][5]. Track via mail/phone alerts. ## Important Disclaimer This guide is for informational purposes based on publicly available sources as of 2026. **Program details can change**; always verify with Novo Nordisk at **(800) 488-5908** or NovoCare.com. Eligibility not guaranteed. Consult your doctor; this is not medical advice. Novo Nordisk PAP is free—no fees[4]. Seek immediate care for bleeding episodes.

Program information last verified: March 30, 2026